Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 996

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

Open access
Razavi, Pedram, Chang, Matthew T., Xu, Guotai, Bandlamudi, Chaitanya, Ross, Dara S., Vasan, Neil, Cai, Yanyan, Bielski, Craig M., Donoghue, Mark T.A., Jonsson, Philip, Penson, Alexander, Shen, Ronglai, Pareja, Fresia, Kundra, Ritika, Middha, Sumit, Cheng, Michael L., Zehir, Ahmet, Kandoth, Cyriac, Patel, Ruchi, Huberman, Kety, Smyth, Lillian M., Jhaveri, Komal, Modi, Shanu, Traina, Tiffany A., Dang, Chau, Zhang, Wen, Weigelt, Britta, Li, Bob T., Ladanyi, Marc, Hyman, David M., Schultz, Nikolaus, Robson, Mark E., Hudis, Clifford, Brogi, Edi, Viale, Agnes, Norton, Larry, Dickler, Maura N., Berger, Michael F., Iacobuzio-Donahue, Christine A., Chandarlapaty, Sarat, Scaltriti, Maurizio, Reis-Filho, Jorge S., Solit, David B., Taylor, Barry S., Baselga, José·2018·Cancer Cell

Abstract

SUMMARY We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 tumors previously exposed to hormonal therapy, we identified an increased number of alterations in genes involved in the mitogen-activated protein kinase (MAPK) pathway and in the estrogen receptor transcriptional machinery. Activating ERBB2 mutations and NF1 loss-of-function mutations were more than twice as common in endocrine resistant tumors. Alterations in other MAPK pathway genes (EGFR, KRAS, among others) and estrogen receptor transcriptional regulators (MYC, CTCF, FOXA1, and TBX3) were also enriched. Altogether, these alterations were present in 22% of tumors, mutually exclusive with ESR1 mutations, and associated with a shorter duration of response to subsequent hormonal therapies

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2018.08.008

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 996

Metadata

Authors
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., Penson, A., Shen, R., Pareja, F., Kundra, R., Middha, S., Cheng, M. L., Zehir, A., Kandoth, C., Patel, R., Huberman, K., Smyth, L. M., Jhaveri, K., Modi, S., Traina, T. A., Dang, C., Zhang, W., Weigelt, B., Li, B. T., Ladanyi, M., Hyman, D. M., Schultz, N., Robson, M. E., Hudis, C., Brogi, E., Viale, A., Norton, L., Dickler, M. N., Berger, M. F., Iacobuzio-Donahue, C. A., Chandarlapaty, S., Scaltriti, M., Reis-Filho, J. S., Solit, D. B., Taylor, B. S., & Baselga, J.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2018-09
Volume
34
Issue
3
Pages
427-438.e6
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2891700678
Cited by
996
References
12
FWCI
23.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. https://app.cochat.ai/papers/10.1016/j.ccell.2018.08.008
The paper
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., Penson, A., Shen, R., Pareja, F., Kundra, R., Middha, S., Cheng, M. L., Zehir, A., Kandoth, C., Patel, R., . . . Baselga, J. (2018). The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. https://doi.org/10.1016/j.ccell.2018.08.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.